GamaMabs Pharma strengthens its governance with the appointment of Martine J George, M.D., as independent board member
Category Archives: Press releases
GamaMabs Pharma raises €15m in series B financing round
BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners, led the round; the funds raised will finance clinical trials for GM102, a therapeutic antibody targeting gynecological cancers
GamaMabs Pharma announces the presentation of new results on 3C23K at TAT congress
GamaMabs Pharma will present new results from its collaboration with the Institut Curie at TAT meeting (Paris, March 2-4 2015) with a poster describing 3C23K antibody efficacy in combination with chemotherapy in PDX models.
Curie-Cancer and GamaMabs Pharma renew their research partnership to develop an antibody for gynecological cancers
Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer.
GamaMabs Pharma signs a Collaboration Agreement with Mayo Clinic
GamaMabs Pharma and Mayo Clinic will collaborate on a study on the efficacy of GamaMabs’ 3C23K antibody in ovarian patient-derived xenografts (PDX) models
GamaMabs Pharma announces two scientific communications on its AMHR2 project
Two studies on AMHR2 project were accepted for a publication in mAbs journal and a poster by Institut Curie (Paris, France) at the 10th Biennial Ovarian Cancer Research Symposium (Seattle, 8-9 September 2014)
GamaMabs Pharma announces two financings totaling €1.1 million
Alto Invest joins GamaMabs investors with a €0.5m equity financing and Bpifrance awards a €0.6m reimbursable aid for the development of 3C23K program in ovarian cancer.
Funding of a new French biotechnologies company specialized in cancer
LFB S.A and Bpifrance announce the creation of GamaMabs Pharma, a new biotechnologies company specialized in the development of a new therapeutic antibody for the treatment of ovarian cancer. The first equity funding led by Bpifrance through the InnoBio fund, next to IRDINOV and IXO Private Equity totalizes €3.1M.